Humacyte’s (HUMA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report released on Monday morning,Benzinga reports. The brokerage currently has a $25.00 target price on the stock.

A number of other research analysts have also recently issued reports on HUMA. BTIG Research reaffirmed a “buy” rating and issued a $6.00 price target on shares of Humacyte in a report on Friday, November 21st. Wall Street Zen downgraded shares of Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st. Benchmark decreased their price target on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. UBS Group reissued a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Humacyte in a report on Monday, December 1st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Humacyte currently has an average rating of “Moderate Buy” and a consensus price target of $8.14.

Humacyte Stock Performance

NASDAQ:HUMA opened at $1.01 on Monday. The stock has a market capitalization of $189.14 million, a P/E ratio of -4.39 and a beta of 1.93. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. Humacyte has a 1 year low of $0.88 and a 1 year high of $4.14. The firm has a 50 day moving average of $1.09 and a 200-day moving average of $1.46.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The business had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.92 million. As a group, sell-side analysts anticipate that Humacyte will post -1.27 EPS for the current fiscal year.

Institutional Trading of Humacyte

Institutional investors have recently bought and sold shares of the business. Prudential Financial Inc. acquired a new position in shares of Humacyte in the 2nd quarter valued at $28,000. Financial Advisors Network Inc. bought a new stake in Humacyte in the second quarter valued at about $28,000. Vanguard Personalized Indexing Management LLC bought a new stake in Humacyte in the second quarter valued at about $30,000. Valeo Financial Advisors LLC acquired a new position in Humacyte in the second quarter valued at about $32,000. Finally, Truist Financial Corp bought a new position in Humacyte during the third quarter worth about $28,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.